Barclays Downgrades Tvardi Therapeutics to Underweight, Lowers Price Target to $3
Benzinga Newsdesk 6 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout downgrades Tvardi Therapeutics (NASDAQ:TVRD) from Equal-Weight to Underweight and lowers the price target from $4 to $3.
Barclays analyst Etzer Darout downgrades Tvardi Therapeutics (NASDAQ:TVRD) from Equal-Weight to Underweight and lowers the price target from $4 to $3.